

IRAQ

Number of new cases

37 382

Number of deaths

21 536

Number of prevalent cases (5-year)

96 416


Statistics at a glance, 2022

	Males	Females	Both sexes
Population	21 347 815	20 817 148	42 164 963
Incidence*			
Number of new cancer cases	15 824	21 558	37 382
Age-standardized incidence rate	132.0	144.1	136.6
Risk of developing cancer before the age of 75 years (cum. risk %)	13.9	14.5	14.1
Top 3 leading cancers (ranked by cases)**	Lung Colorectum Leukaemia	Breast Thyroid Leukaemia	Breast Lung Colorectum
Mortality*			
Number of cancer deaths	10 403	11 133	21 536
Age-standardized mortality rate	91.9	79.5	84.4
Risk of dying from cancer before the age of 75 years (cum. risk %)	9.7	8.4	9.0
Top 3 leading cancers (ranked by deaths)**	Lung Leukaemia Colorectum	Breast Leukaemia Brain CNS	Breast Lung Leukaemia
Prevalence*			
5-year prevalent cases	37 307	59 109	96 416



Top 5 most frequent cancers**

Males




Total: 15 824

Rank	Cancer site	Number of cases	Percent
1st	Lung	2 364	14.9%
2nd	Colorectum	1 312	8.3%
3rd	Leukaemia	1 192	7.5%
4th	Prostate	1 187	7.5%
5th	Bladder	1 146	7.2%
-	Others	8 623	54.5%

Number of new cases in 2022, males, all ages

Females




Total: 21 558

Rank	Cancer site	Number of cases	Percent
1st	Breast	8 626	40.0%
2nd	Thyroid	1 241	5.8%
3rd	Leukaemia	1 066	4.9%
4th	Colorectum	1 008	4.7%
5th	Ovary	1 002	4.6%
-	Others	8 615	40.0%

Number of new cases in 2022, females, all ages

Both sexes



Total: 37 382

Rank	Cancer site	Number of cases	Percent
1st	Breast	8 626	23.1%
2nd	Lung	2 814	7.5%
3rd	Colorectum	2 320	6.2%
4th	Leukaemia	2 258	6.0%
5th	NHL	1 930	5.2%
-	Others	19 434	52.0%

Number of new cases in 2022, both sexes, all ages

Incidence, Mortality and Prevalence by cancer site

Cancer	New cases				Deaths				5-year prevalence	
	Number	Rank	(%)	Cum.risk	Number	Rank	(%)	Cum.risk	Number	Prop. (per 100 000)
Breast	8 626	1	23.1	6.0	3 372	1	15.7	2.5	24 995	120.1
Lung	2 814	2	7.5	1.5	2 613	2	12.1	1.4	3 747	8.9
Colorectum	2 320	3	6.2	1.0	1 438	5	6.7	0.64	6 149	14.6
Leukaemia	2 258	4	6.0	0.66	1 694	3	7.9	0.56	6 512	15.4
NHL	1 930	5	5.2	0.71	1 013	7	4.7	0.42	5 808	13.8
Brain CNS	1 769	6	4.7	0.55	1 485	4	6.9	0.52	6 005	14.2
Thyroid	1 618	7	4.3	0.46	231	18	1.1	0.11	5 047	12.0
Bladder	1 494	8	4.0	0.78	726	10	3.4	0.36	4 135	9.8
Stomach	1 267	9	3.4	0.58	1 060	6	4.9	0.49	2 049	4.9
Prostate	1 187	10	3.2	1.5	426	13	2.0	0.30	2 493	11.7
Ovary	1 002	11	2.7	0.73	693	11	3.2	0.59	2 709	13.0
Hodgkin lymphoma	894	12	2.4	0.22	330	16	1.5	0.08	2 938	7.0
Kidney	858	13	2.3	0.34	448	12	2.1	0.20	2 443	5.8
Liver	807	14	2.2	0.39	777	8	3.6	0.39	1 134	2.7
Pancreas	766	15	2.0	0.40	752	9	3.5	0.40	898	2.1
Corpus uteri	688	16	1.8	0.62	196	20	0.91	0.18	2 180	10.5
Larynx	544	17	1.5	0.29	377	15	1.8	0.20	1 503	3.6
Multiple myeloma	481	18	1.3	0.23	404	14	1.9	0.21	1 228	2.9
Cervix uteri	311	19	0.83	0.25	216	19	1.0	0.19	877	4.2
Lip, oral cavity	293	20	0.78	0.13	171	21	0.79	0.08	791	1.9
Oesophagus	280	21	0.75	0.14	269	17	1.2	0.13	445	1.1
Testis	239	22	0.64	0.11	52	25	0.24	0.04	798	3.7
Gallbladder	178	23	0.48	0.09	155	22	0.72	0.08	262	0.62
Nasopharynx	175	24	0.47	0.06	116	23	0.54	0.04	519	1.2
Salivary glands	135	25	0.36	0.05	63	24	0.29	0.03	395	0.94
Melanoma	111	26	0.30	0.05	31	26	0.14	0.01	345	0.82
Kaposi sarcoma	51	27	0.14	0.02	17	28	0.08	0.01	119	0.28
Vulva	28	28	0.08	0.03	14	29	0.07	0.01	76	0.37
Hypopharynx	27	29	0.07	0.01	10	31	0.05	0.00	49	0.12
Mesothelioma	27	29	0.07	0.01	24	27	0.11	0.01	42	0.10
Oropharynx	21	31	0.06	0.01	12	30	0.06	0.01	53	0.13
Vagina	19	32	0.05	0.02	10	31	0.05	0.01	49	0.24
All cancers	37 382	-	-	14.1	21 536	-	-	9.0	96 416	-
All cancers excl. NMSC	36 982	-	-	14.0	21 428	-	-	9.0	95 202	-

Data source and methods

Incidence



Country-specific data source: [{"dt_list": "National cancer registry" }]
Method: National (or sub-national with coverage greater than 50%) rates projected to 2022

Mortality

Country-specific data source: No data
Method: Estimated from national incidence estimates by modelling, using mortality:incidence ratios derived from survival estimation

Prevalence

Computed using sex-; site- and age-specific incidence to 1-;3- and 5-year prevalence ratios from Nordic countries for the period (2011-2020), and scaled using Human Development Index (HDI) ratios.



* includes non-melanoma skin cancer (NMSC)

** NMSC included in other cancers

Age standardization using world population ([see link](#))

References

Website citation

Ferlay J, Ervik M, Lam F, Laversanne M, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2024). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: <https://gco.iarc.who.int/today>, accessed [DD Month YYYY].

Cancer incidence and mortality data

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021 Feb 4. doi: 10.3322/caac.21660. Epub ahead of print. PMID: 33538338.

Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A, Bray F. Cancer statistics for the year 2020: An overview. Int J Cancer. 2021 Apr 5. doi: 10.1002/ijc.33588. Epub ahead of print. PMID: 33818764.

